Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials

View ORCID ProfileSoheil Hassanipour, View ORCID ProfileMorteza Arab-Zozani, View ORCID ProfileBahman Amani, View ORCID ProfileForough Heidarzad, View ORCID ProfileMohammad Fathalipour, View ORCID ProfileRudolph Martinez-de-Hoyo
doi: https://doi.org/10.1101/2021.02.14.21251693
Soheil Hassanipour
aGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Soheil Hassanipour
  • For correspondence: soheil.epid@gmail.com
Morteza Arab-Zozani
bSocial Determinants of Health Research Center, Birjand University of Medical sciences, Birjand, Iran. Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Morteza Arab-Zozani
  • For correspondence: arab.hta@gmail.com arab.hta@gmail.com
Bahman Amani
cMaster of Health Technology Assessment, Faculty of Health, Tehran University of Medical Sciences, Tehran, Iran. Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bahman Amani
  • For correspondence: b89amani@yahoo.com
Forough Heidarzad
dGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Forough Heidarzad
  • For correspondence: foroughhdz@gmail.com
Mohammad Fathalipour
eDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammad Fathalipour
  • For correspondence: m.fathalipour@yahoo.com
Rudolph Martinez-de-Hoyo
fMedical Doctor, MSN Labs Americas, Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rudolph Martinez-de-Hoyo
  • For correspondence: rudolphmartinezdehoyo@yahoo.es
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The novel coronavirus outbreak began in late December 2019 and rapidly spread worldwide, critically impacting public health systems. A number of already approved and marketed drugs are being tested for repurposing, including Favipiravir. We aim to investigate the efficacy and safety of Favipiravir in treatment of COVID-19 patients through a systematic review and meta-analysis. This systematic review and meta-analysis were reported in accordance with the PRISMA statement. We registered the protocol in the PROSPERO (CRD42020180032). All clinical trials which addressed the safety and efficacy of Favipiravir in comparison to other control groups for treatment of patients with confirmed infection with SARS-CoV2 were included. We searched electronic databases including LitCovid hub/PubMed, Scopus, ISI web of Sciences, Cochrane, and Scientific Information Database up to 31 December 2020. We assessed the risk of bias of the included studies using Cochrane Collaboration criteria. All analyses were performed using the Comprehensive Meta-Analysis software version 2, and the risk ratio index was calculated. Egger and Begg test was used for assessing publication bias. Nine studies were included in our meta-analysis. The results of the meta-analysis revealed a significant clinical improvement in the Favipiravir group versus the control group during seven days after hospitalization (RR=1.24, 95% CI: 1.09-1.41; P=0.001). Viral clearance was more in 14 days after hospitalization in Favipiravir group than control group, but this finding marginally not significant (RR=1.11, 95% CI: 0.98-1.25; P=0.094). Requiring supplemental oxygen therapy in the Favipiravir group was 7% less than the control group, (RR=0.93, 95% CI: 0.67-1.28; P=0.664). Transferred to ICU and adverse events were not statistically different between two groups. The mortality rate in the Favipiravir group was approximately 30% less than the control group, but this finding not statistically significant. Favipiravir possibly exerted no significant beneficial effect in the term of mortality in the general group of patients with mild to moderate COVID-19. We should consider that perhaps the use of antiviral once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting.

Competing Interest Statement

MSN produces favipiravir (Favilow). The authors declared no conflict of interest.

Clinical Protocols

https://bmjopen.bmj.com/content/10/7/e039730

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We published the protocol in the BMJ open journal. due to the design of this study, there is no need for ethics approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All relevant data included in the manuscript and also is available by contacting the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 17, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials
Soheil Hassanipour, Morteza Arab-Zozani, Bahman Amani, Forough Heidarzad, Mohammad Fathalipour, Rudolph Martinez-de-Hoyo
medRxiv 2021.02.14.21251693; doi: https://doi.org/10.1101/2021.02.14.21251693
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials
Soheil Hassanipour, Morteza Arab-Zozani, Bahman Amani, Forough Heidarzad, Mohammad Fathalipour, Rudolph Martinez-de-Hoyo
medRxiv 2021.02.14.21251693; doi: https://doi.org/10.1101/2021.02.14.21251693

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (196)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5681)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (866)
  • Geriatric Medicine (88)
  • Health Economics (231)
  • Health Informatics (762)
  • Health Policy (390)
  • Health Systems and Quality Improvement (252)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6474)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (92)
  • Neurology (847)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (163)
  • Occupational and Environmental Health (260)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (106)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (966)
  • Public and Global Health (2228)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)